Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel RNA Blood Test Launched for Fibromyalgia

By LabMedica International staff writers
Posted on 10 Apr 2018
It is estimated that about five million Americans suffer from fibromyalgia, a poorly understood disorder characterized by deep tissue pain, fatigue, headaches, mood swings and insomnia. More...
It often takes years for a patient to be diagnosed with fibromyalgia and some doctors still refuse to recognize it as a disease.

An innovative new blood test has been launched that uses RNA analysis to diagnose patients with fibromyalgia and can identify fibromyalgia within a week and with over 90% accuracy. Ribonucleic acid (RNA) is a molecule that plays an essential role in sensing and communicating responses to cellular signals. Unlike DNA tests, which can only predict the likelihood of someone having a disease, RNA tests show what is actually happening at a cellular level.

The test is called IsolateFibromyalgia (IquityLabs, Nashville, TN, USA) and this breakthrough RNA blood test can ‘rule in’ or ‘rule out’ a suspected diagnosis of fibromyalgia and the technology delivers accuracy rates that exceed 90%. The test uses a simple blood draw to analyze RNA patterns found in a patient sample to see if it is consistent with a diagnosis of fibromyalgia syndrome. The test costs USD 599.

Scientists from the company used samples from diagnosed patients as well as healthy subjects, and applied machine learning to develop the proprietary algorithm that can accurately identify fibromyalgia syndrome. These scientists studied almost 600 subjects, including patients with: fibromyalgia, rheumatoid arthritis, systemic lupus, other disease controls: endocrine, rheumatologic, dermatologic, patients with clinically diagnosed depression and healthy individuals. Standard calculations of sensitivity and specificity were employed to determine the accuracy of the results, which are greater than 90%.

Chase Spurlock, PhD, CEO of IQuity said, “When we look at RNA in blood, we’re looking at a snapshot of what’s actually taking place at that moment inside the patient’s blood cells. Using that information, we can decipher those molecular communication patterns, those RNA signals that are taking place, and figure out does it look like fibromyalgia syndrome or does it look like something else? In the case of fibromyalgia, we completed our clinical validation studies and our accuracy is at 94% and the sensitivity and specificity are greater than 90% as well. So, it’s a highly actionable test.”

Related Links:
IquityLabs

New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Collection and Transport System
PurSafe Plus®
Clinical Chemistry System
P780
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.